Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness or remission. Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness.To date, lupus has no known cause or cure. Early detection and treatment are the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, antimalarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, like those used in the treatment of cancer, are also used to suppress the immune system in lupus patients. A new edition of this established and well-regarded reference combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus, Sixth Edition, is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a reference work for hospital libraries.
• Synthesizes advances in SLE pathogenesis, from genetics and epigenetics to innate and adaptive immunopathogenesis
• Covers approved and investigational therapies including type I interferon blockade and CAR-T cell approaches
• Addresses precision medicine frameworks incorporating AI-driven monitoring and molecular patient stratification
• Provides international perspectives on SLE epidemiology, health disparities, and outcomes
1. Lahita's Systemic Lupus Erythematosus - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iv 6. Dedication - p. Page iv 7. Contributors - p. Page v 8. Foreword - p. Page viii 9. Foreword from the First Edition - p. Page ix 10. Preface to Edition 6, Systemic Lupus Erythematosus - p. Page x 11. Acknowledgment - p. Page xi 12. History of lupus erythematosus - p. Page xi 13. List of Illustrations - p. Page xv 14. List of Tables - p. Page xvi 15. Chapter 1 : Major histocompatibility complex and SLE - p. Page xvi 16. Chapter 2 : Lupus susceptibility genes - p. Page 20 17. Chapter 3 : Epigenetics in systemic lupus erythematosus and the integration of molecular pathways - p. Page 30 18. Chapter 4 : Autoantigens, antigenic mimicry, and immune complexes - p. Page 53 19. Chapter 5 : B-cell biology, tolerance, and autoantibodies - p. Page 69 20. Chapter 6 : T-cell biology, tolerance, and regulation - p. Page 77 21. Chapter 7 : Polymorphonuclear cells - p. Page 91 22. Chapter 8 : Metabolic and mitochondrial dysfunction in SLE - p. Page 104 23. Chapter 9 : Immunopathogenesis: the role of mucosal and skin microbiota in SLE - p. Page 113 24. Chapter 10 : Complement and SLE - p. Page 127 25. Chapter 11 : Interferons and cytokines in SLE pathogenesis and therapy - p. Page 155 26. Chapter 12 : Innate immunity in SLE pathogenesis - p. Page 176 27. Chapter 13 : Sex bias in SLE - p. Page 186 28. Chapter 14 : Mechanisms of tissue injury in lupus nephritis - p. Page 195 29. Chapter 15 : The skin - p. Page 213 30. Chapter 16 : The brain in SLE: mechanisms and detection of injury and therapeutic strategies - p. Page 224 31. Chapter 17 : The role of infections in SLE pathogenesis - p. Page 240 32. Chapter 18 : Tissue injury—the biology: SLE-associated vascular disease and antiphospholipid syndrome - p. Page 265 33. Chapter 19 : Epidemiology of SLE and related diseases: incidence, prevalence, and mortality - p. Page 279 34. Chapter 20 : The clinical presentation of systemic lupus erythematosus and laboratory diagnosis - p. Page 300 35. Chapter 21 : Passively acquired lupus in the fetus and neonate - p. Page 319 36. Chapter 22 : Systemic lupus erythematosus in children - p. Page 352 37. Chapter 23 : Environmental and drug-induced lupus - p. Page 373 38. Chapter 24 : Reproductive health - p. Page 387 39. Chapter 25 : Monitoring disease activity - p. Page 403 40. Chapter 26 : Overlap syndromes - p. Page 421 41. Chapter 27 : Nervous system - p. Page 429 42. Chapter 28 : Skin - p. Page 441 43. Chapter 29 : Kidney disease - p. Page 465 44. Chapter 30 : Cardiovascular disease in lupus - p. Page 491 45. Chapter 31 : Pulmonary manifestations of systemic lupus erythematosus - p. Page 513 46. Chapter 32 : GI hepatic and nonhepatic diseases - p. Page 527 47. Chapter 33 : Musculoskeletal system: articular disease, myositis, and bone metabolism - p. Page 538 48. Chapter 34 : Clinical presentation of antiphospholipid syndrome - p. Page 555 49. Chapter 35 : Hematology: cytopenias - p. Page 570 50. Chapter 36 : Malignancy risk and screening - p. Page 581 51. Chapter 37 : Antimalarial drugs (and lupus) - p. Page 593 52. Chapter 38 : Glucocorticoids - p. Page 606 53. Chapter 39 : Immunosuppressive therapy in SLE - p. Page 619 54. Chapter 40 : Pipeline therapies and future drug development - p. Page 644 55. Chapter 41 : Challenges of systemic lupus clinical trials - p. Page 668 56. Index - p. Page 680
Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness or remission. Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness.To date, lupus has no known cause or cure. Early detection and treatment are the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, antimalarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, like those used in the treatment of cancer, are also used to suppress the immune system in lupus patients. A new edition of this established and well-regarded reference combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus, Sixth Edition, is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a reference work for hospital libraries.
• Synthesizes advances in SLE pathogenesis, from genetics and epigenetics to innate and adaptive immunopathogenesis
• Covers approved and investigational therapies including type I interferon blockade and CAR-T cell approaches
• Addresses precision medicine frameworks incorporating AI-driven monitoring and molecular patient stratification
• Provides international perspectives on SLE epidemiology, health disparities, and outcomes
1. Lahita's Systemic Lupus Erythematosus - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page ii 4. Table of Contents - p. Page iii 5. Copyright - p. Page iv 6. Dedication - p. Page iv 7. Contributors - p. Page v 8. Foreword - p. Page viii 9. Foreword from the First Edition - p. Page ix 10. Preface to Edition 6, Systemic Lupus Erythematosus - p. Page x 11. Acknowledgment - p. Page xi 12. History of lupus erythematosus - p. Page xi 13. List of Illustrations - p. Page xv 14. List of Tables - p. Page xvi 15. Chapter 1 : Major histocompatibility complex and SLE - p. Page xvi 16. Chapter 2 : Lupus susceptibility genes - p. Page 20 17. Chapter 3 : Epigenetics in systemic lupus erythematosus and the integration of molecular pathways - p. Page 30 18. Chapter 4 : Autoantigens, antigenic mimicry, and immune complexes - p. Page 53 19. Chapter 5 : B-cell biology, tolerance, and autoantibodies - p. Page 69 20. Chapter 6 : T-cell biology, tolerance, and regulation - p. Page 77 21. Chapter 7 : Polymorphonuclear cells - p. Page 91 22. Chapter 8 : Metabolic and mitochondrial dysfunction in SLE - p. Page 104 23. Chapter 9 : Immunopathogenesis: the role of mucosal and skin microbiota in SLE - p. Page 113 24. Chapter 10 : Complement and SLE - p. Page 127 25. Chapter 11 : Interferons and cytokines in SLE pathogenesis and therapy - p. Page 155 26. Chapter 12 : Innate immunity in SLE pathogenesis - p. Page 176 27. Chapter 13 : Sex bias in SLE - p. Page 186 28. Chapter 14 : Mechanisms of tissue injury in lupus nephritis - p. Page 195 29. Chapter 15 : The skin - p. Page 213 30. Chapter 16 : The brain in SLE: mechanisms and detection of injury and therapeutic strategies - p. Page 224 31. Chapter 17 : The role of infections in SLE pathogenesis - p. Page 240 32. Chapter 18 : Tissue injury—the biology: SLE-associated vascular disease and antiphospholipid syndrome - p. Page 265 33. Chapter 19 : Epidemiology of SLE and related diseases: incidence, prevalence, and mortality - p. Page 279 34. Chapter 20 : The clinical presentation of systemic lupus erythematosus and laboratory diagnosis - p. Page 300 35. Chapter 21 : Passively acquired lupus in the fetus and neonate - p. Page 319 36. Chapter 22 : Systemic lupus erythematosus in children - p. Page 352 37. Chapter 23 : Environmental and drug-induced lupus - p. Page 373 38. Chapter 24 : Reproductive health - p. Page 387 39. Chapter 25 : Monitoring disease activity - p. Page 403 40. Chapter 26 : Overlap syndromes - p. Page 421 41. Chapter 27 : Nervous system - p. Page 429 42. Chapter 28 : Skin - p. Page 441 43. Chapter 29 : Kidney disease - p. Page 465 44. Chapter 30 : Cardiovascular disease in lupus - p. Page 491 45. Chapter 31 : Pulmonary manifestations of systemic lupus erythematosus - p. Page 513 46. Chapter 32 : GI hepatic and nonhepatic diseases - p. Page 527 47. Chapter 33 : Musculoskeletal system: articular disease, myositis, and bone metabolism - p. Page 538 48. Chapter 34 : Clinical presentation of antiphospholipid syndrome - p. Page 555 49. Chapter 35 : Hematology: cytopenias - p. Page 570 50. Chapter 36 : Malignancy risk and screening - p. Page 581 51. Chapter 37 : Antimalarial drugs (and lupus) - p. Page 593 52. Chapter 38 : Glucocorticoids - p. Page 606 53. Chapter 39 : Immunosuppressive therapy in SLE - p. Page 619 54. Chapter 40 : Pipeline therapies and future drug development - p. Page 644 55. Chapter 41 : Challenges of systemic lupus clinical trials - p. Page 668 56. Index - p. Page 680
